BioCentriq Names New CEO

BioCentriq, a cell therapy contract development and manufacturing organization (CDMO), has appointed Syed T. Husain as its new Chief Executive Officer (CEO), and as a member of the Board of Directors.
 
Husain offers extensive expertise in CDMO development and manufacturing services, with a deep understanding of the cell and gene therapy supply and value chains. His experience spans the entire drug development and commercialization lifecycle, including over 20 years of strategic management, leading companies through rapid growth, go-to-market innovation, and industry disruption.
 
“Syed’s extensive experience in CDMO business expansion will be pivotal in ensuring BioCentriq’s leadership in manufacturing innovation and in spearheading the clinical to commercial manufacturing of cutting-edge cell therapies,” said James Park, Chairman of the Board at BioCentriq.
 
Husain’s expertise will guide BioCentriq through its next phase of growth. He will rely on his most recent experience as Chief Commercial Officer at Resilience. During this time, he developed an industry-leading commercial organization, serving established (Biologics, Vaccines) and emerging modalities (Cell & Gene Therapy, Nucleic Acids). He established a multi-billion-dollar backlog and opportunity pipeline, securing transformative deals with top pharmaceutical and biotech companies. Husain also fostered a customer-centered culture that deeply resonated with customers and supported long-term, patient-focused growth.
 
Prior to his time with Resilience, he served in CDMO leadership roles at Emergent BioSolutions, Alcami Corporation, and Lonza.
 
“As BioCentriq moves into its next phase of growth, we’re committed to strengthening our capabilities even further,” said Husain. “Our goal is to drive the approval of new CGT modalities by offering a complete end-to-end solution—from clinical to commercial manufacturing—ensuring that life-changing therapies reach the patients who need them most.”